Robert Weinstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert Weinstein has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Michelle Vauthrin
Transfusion Medicine and Apheresis Service, UMass Memorial Medical Center, Worcester, Massachusetts
14 shared publicationsMindy Greene
Transfusion Medicine and Apheresis Service, UMass Memorial Medical Center, Worcester, Massachusetts
14 shared publicationsJeanne Linden
Transfusion Medicine and Apheresis Service, UMass Memorial Medical Center, Worcester, Massachusetts
8 shared publicationsYong Zhao
Transfusion Medicine and Apheresis Service, UMass Memorial Medical Center, Worcester, Massachusetts
8 shared publicationsJeffrey A. Bailey
Transfusion Medicine and Apheresis Service, UMass Memorial Medical Center, Worcester, Massachusetts
7 shared publicationsPatricia St. Pierre
Transfusion Medicine and Apheresis Service, UMass Memorial Medical Center, Worcester, Massachusetts
6 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (3) , e70135
Can Plasma Exchange Be Used to Lower the Circulating Burden of Microplastics in Human Patients?
Microplastic particles (MP) from industrial products and degradation of plastic waste are ubiquitous in our environment and convey serious potential risks to human health. There is currently no established method for removing MP from the human body. MP circulate in the blood and have been found in the eluate plasma from double filtration plasmapheresis procedures, suggesting that plasmapheresis could be used to remove MP from the body. We have measured circulating MP in the blood of 114 patients before and after 174 1‐plasma‐volume therapeutic plasma exchange (TPE) procedures using the Spectra Optia Apheresis System and have shown that circulating MP are reduced by TPE. The reduction is obscured at low starting levels of MP because of leaching of MP back into the circulation from the plastic apheresis tubing set. Nonetheless, this is the first demonstration that it is possible to reduce circulating MP in human patients.
- 21 May 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (3) , e70135
Open AccessCan Plasma Exchange Be Used to Lower the Circulating Burden of Microplastics in Human Patients?
Microplastic particles (MP) from industrial products and degradation of plastic waste are ubiquitous in our environment and convey serious potential risks to human health. There is currently no established method for removing MP from the human body. MP circulate in the blood and have been found in the eluate plasma from double filtration plasmapheresis procedures, suggesting that plasmapheresis could be used to remove MP from the body. We have measured circulating MP in the blood of 114 patients before and after 174 1‐plasma‐volume therapeutic plasma exchange (TPE) procedures using the Spectra Optia Apheresis System and have shown that circulating MP are reduced by TPE. The reduction is obscured at low starting levels of MP because of leaching of MP back into the circulation from the plastic apheresis tubing set. Nonetheless, this is the first demonstration that it is possible to reduce circulating MP in human patients.
- Open Access
- 13 April 2026
- Published by Elsevier in SSRN Electronic Journal
Therapeutic Plasma Exchange to Deplete Microplastic Particles from the Bloodstream of Patients
PurposeMicroplastic (1 µm to 5 mm) particles (MP) from of plastic waste in our environment may be inhaled, absorbed or ingested. They may enter the heart, lungs, GI tract and other systems and cause adverse effects including hemolysis, platelet aggregation, thrombosis or organ dysfunction. There is no established method for removing MP from the body. MP have been found in the eluate plasma from double filtration plasmapheresis, suggesting that circulating MP may be removed by apheresis.MethodsTherapeutic plasma exchange (TPE) by centrifugation was performed on ambulatory patients. Blood continuously drawn from an arm vein flows into a centrifuge where the plasma and red blood cells are separated. The plasma is collected while the red blood cells are returned to the patient via the opposite arm, together with a solution of 5% human albumin. 100 µL of antecubital blood obtained before and after TPE, were applied to test cards, air dried and sent for testing by PlasticTox.ResultsTwenty one patients whose pre-apheresis MP were ≥ 30/100 µL underwent 22 TPE. Mean [median] ± SEM MP were 50.61 [43.0] ± 4.5 pre-TPE and 19.26 [16.0] ± 3.37 post-TPE (P<0.001 by Wilcoxon Signed Rank Test). The calculated effect size was 1.58 (Cohen’s D). All TPE procedures were well-tolerated without adverse effects.ConclusionMP circulate in human blood and are susceptible to removal using plasma exchange. To our knowledge, this is the first clinical procedure shown to significantly remove MP from the body.
- 13 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTherapeutic Plasma Exchange to Deplete Microplastic Particles from the Bloodstream of Patients
PurposeMicroplastic (1 µm to 5 mm) particles (MP) from of plastic waste in our environment may be inhaled, absorbed or ingested. They may enter the heart, lungs, GI tract and other systems and cause adverse effects including hemolysis, platelet aggregation, thrombosis or organ dysfunction. There is no established method for removing MP from the body. MP have been found in the eluate plasma from double filtration plasmapheresis, suggesting that circulating MP may be removed by apheresis.MethodsTherapeutic plasma exchange (TPE) by centrifugation was performed on ambulatory patients. Blood continuously drawn from an arm vein flows into a centrifuge where the plasma and red blood cells are separated. The plasma is collected while the red blood cells are returned to the patient via the opposite arm, together with a solution of 5% human albumin. 100 µL of antecubital blood obtained before and after TPE, were applied to test cards, air dried and sent for testing by PlasticTox.ResultsTwenty one patients whose pre-apheresis MP were ≥ 30/100 µL underwent 22 TPE. Mean [median] ± SEM MP were 50.61 [43.0] ± 4.5 pre-TPE and 19.26 [16.0] ± 3.37 post-TPE (P<0.001 by Wilcoxon Signed Rank Test). The calculated effect size was 1.58 (Cohen’s D). All TPE procedures were well-tolerated without adverse effects.ConclusionMP circulate in human blood and are susceptible to removal using plasma exchange. To our knowledge, this is the first clinical procedure shown to significantly remove MP from the body.
- 23 February 2024
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 39 (1) , e22108
Writing manuscripts for peer review
Little instruction in writing manuscripts for peer review is provided in nursing school or medical school. To relatively inexperienced would‐be authors, including junior physicians and allied health professionals, this avenue of professional communication may sometimes seem to be unattainable. Yet many of them are energetic and insightful, and have the potential to make contributions to the literature. This article aims to provide an explanation of the components of the peer review manuscript and advice regarding how to go about writing one so as to overcome the writer's block that inexperienced authors may frequently experience.
- 23 February 2024
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 39 (1) , e22108
Writing manuscripts for peer review
Little instruction in writing manuscripts for peer review is provided in nursing school or medical school. To relatively inexperienced would‐be authors, including junior physicians and allied health professionals, this avenue of professional communication may sometimes seem to be unattainable. Yet many of them are energetic and insightful, and have the potential to make contributions to the literature. This article aims to provide an explanation of the components of the peer review manuscript and advice regarding how to go about writing one so as to overcome the writer's block that inexperienced authors may frequently experience.
- 24 February 2023
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 62 (2) , 103675
Basic principles of therapeutic plasma exchange
- 24 February 2023
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 62 (2) , 103675
Basic principles of therapeutic plasma exchange
- 29 December 2020
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 36 (3) , 465-469
Writing scientific case reports for top‐line journals
The venerable clinical case report has been largely reduced to the status of commodity in the present age of dedicated case report journals. Top‐line clinical journals may discourage or even refuse to accept clinical case reports due to their potential adverse effect on the impact factor of the journal. But while the traditional clinical case report, that presents a case history and attempts to extrapolate a lesson from it, may have fallen out of favor, there remains a need for astute clinical observations that serve to stimulate the generation of hypotheses and may lead, ultimately, to medical breakthroughs. Clinicians are very much capable of employing scientific reasoning when approaching an unusual clinical situation. By remaining up to date with the literature, and determining, at the outset of the case, what lessons may be learned from it, they can formulate a scientific approach, using clinical methods, to result in meaningful contributions to the literature in top‐line journals.
- 29 December 2020
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 36 (3) , 465-469
Writing scientific case reports for top‐line journals
The venerable clinical case report has been largely reduced to the status of commodity in the present age of dedicated case report journals. Top‐line clinical journals may discourage or even refuse to accept clinical case reports due to their potential adverse effect on the impact factor of the journal. But while the traditional clinical case report, that presents a case history and attempts to extrapolate a lesson from it, may have fallen out of favor, there remains a need for astute clinical observations that serve to stimulate the generation of hypotheses and may lead, ultimately, to medical breakthroughs. Clinicians are very much capable of employing scientific reasoning when approaching an unusual clinical situation. By remaining up to date with the literature, and determining, at the outset of the case, what lessons may be learned from it, they can formulate a scientific approach, using clinical methods, to result in meaningful contributions to the literature in top‐line journals.
- 7 August 2020
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 35 (5) , 469-476
Surviving peer review
The process of publishing original work in a peer review journal is not complete at the point where the manuscript is first submitted. The journal editors will submit the manuscript to peer review whereby outside experts are asked to vet the manuscript for scientific merit, originality and quality. Reviewers' comments are meant to help authors strengthen their manuscripts for potential publication. Authors benefit from this feedback and should approach the reviewers as volunteer consultants rather than as critics. Authors should respond to all reviewers' comments, completely and politely addressing the points raised. This article is meant to assist junior or inexperienced authors to understand the process of peer review and to function effectively within the process in order to succeed in having their manuscripts published.
- 7 August 2020
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 35 (5) , 469-476
Surviving peer review
The process of publishing original work in a peer review journal is not complete at the point where the manuscript is first submitted. The journal editors will submit the manuscript to peer review whereby outside experts are asked to vet the manuscript for scientific merit, originality and quality. Reviewers' comments are meant to help authors strengthen their manuscripts for potential publication. Authors benefit from this feedback and should approach the reviewers as volunteer consultants rather than as critics. Authors should respond to all reviewers' comments, completely and politely addressing the points raised. This article is meant to assist junior or inexperienced authors to understand the process of peer review and to function effectively within the process in order to succeed in having their manuscripts published.
- 12 June 2020
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 35 (4) , 358-366
How to write a manuscript for peer review
Writing a manuscript for peer review is an art for which little formal preparation is provided during the education of physicians, scientists, and allied health professionals. At the same time, publishing their work may be central to their career ambitions. This article provides an explanation of the purpose and expected content of the components of a peer review manuscript and advice regarding how to go about writing one. It aims to somewhat demystify the process of scientific writing and render it accessible to more members of the American Society for Apheresis.
- 12 June 2020
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 35 (4) , 358-366
How to write a manuscript for peer review
Writing a manuscript for peer review is an art for which little formal preparation is provided during the education of physicians, scientists, and allied health professionals. At the same time, publishing their work may be central to their career ambitions. This article provides an explanation of the purpose and expected content of the components of a peer review manuscript and advice regarding how to go about writing one. It aims to somewhat demystify the process of scientific writing and render it accessible to more members of the American Society for Apheresis.
- 19 August 2019
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 34 (6) , 661-665
Performance characteristics of the PowerFlow apheresis port: Early experience
We prospectively evaluated the Bard PowerFlow Implantable Apheresis IV Port in four patients undergoing outpatient therapeutic plasma exchange over 18 to 97 days. Three had bilateral internal jugular access ports, and one had a single left internal jugular access port for the inlet line with return via antecubital vein. Two patients receiving 5% albumin as replacement fluid achieved peak inlet flow of 99 ± 5 mL/min and 101 ± 6 mL/min, and peak plasma flow of 53 ± 6 and 47 ± 6 mL/min, respectively. Two patients receiving plasma as replacement fluid achieved peak inlet flow of 46 ± 7 and 85 ± 4 mL/min and peak plasma flow of 27 ± 3 and 35 ± 4 mL/min, respectively. Apheresis nurses accessed the ports on the first attempt in all procedures. Pressure alarms occurred in 6 of 47 procedures and were easily resolved by lowering the inlet rate by 10% in 5 of them. The PowerFlow shows promise as an implantable venous access device for apheresis.
- 19 August 2019
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 34 (6) , 661-665
Performance characteristics of the PowerFlow apheresis port: Early experience
We prospectively evaluated the Bard PowerFlow Implantable Apheresis IV Port in four patients undergoing outpatient therapeutic plasma exchange over 18 to 97 days. Three had bilateral internal jugular access ports, and one had a single left internal jugular access port for the inlet line with return via antecubital vein. Two patients receiving 5% albumin as replacement fluid achieved peak inlet flow of 99 ± 5 mL/min and 101 ± 6 mL/min, and peak plasma flow of 53 ± 6 and 47 ± 6 mL/min, respectively. Two patients receiving plasma as replacement fluid achieved peak inlet flow of 46 ± 7 and 85 ± 4 mL/min and peak plasma flow of 27 ± 3 and 35 ± 4 mL/min, respectively. Apheresis nurses accessed the ports on the first attempt in all procedures. Pressure alarms occurred in 6 of 47 procedures and were easily resolved by lowering the inlet rate by 10% in 5 of them. The PowerFlow shows promise as an implantable venous access device for apheresis.
- 10 August 2019
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 34 (6) , 656-660
Optimization of infusional calcium gluconate for prevention of hypocalcemic reactions during therapeutic plasma exchange
We sought to optimize direct intravenous infusion of calcium gluconate (CaGlu) for maintaining plasma ionized calcium concentration ([Ca2+]) and preventing hypocalcemic reactions during 34 consecutive 1‐volume therapeutic plasma exchanges (TPEs) in eight patients. CaGlu, 2 g in 50 mL of 0.9% NaCl, was prepared by our hospital pharmacy and infused at either 1.0 or 1.6 g/h during alternate TPE. Plasma [Ca2+] was monitored at intervals of 20 to 30 minutes. At 1 g/h of CaGlu, plasma [Ca2+] fell by 8.35% after 40 to 50 minutes and then plateaued. At 1.6 g/h of CaGlu, plasma [Ca2+] fell by 6% after 20 to 30 minutes and then plateaued. The difference at 40 to 50 minutes was significant (P = .015). Hypocalcemic reactions were noted in three patients during 5 of 17 TPE at 1.0 g/h (all after 40 to 60 minutes) but 0 of 17 TPE at 1.6 g/h (P = .044). CaGlu at 1.6 g/h stabilized plasma [Ca2+] and appears to prevent hypocalcemic reactions during TPE.
- 10 August 2019
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 34 (6) , 656-660
Optimization of infusional calcium gluconate for prevention of hypocalcemic reactions during therapeutic plasma exchange
We sought to optimize direct intravenous infusion of calcium gluconate (CaGlu) for maintaining plasma ionized calcium concentration ([Ca2+]) and preventing hypocalcemic reactions during 34 consecutive 1‐volume therapeutic plasma exchanges (TPEs) in eight patients. CaGlu, 2 g in 50 mL of 0.9% NaCl, was prepared by our hospital pharmacy and infused at either 1.0 or 1.6 g/h during alternate TPE. Plasma [Ca2+] was monitored at intervals of 20 to 30 minutes. At 1 g/h of CaGlu, plasma [Ca2+] fell by 8.35% after 40 to 50 minutes and then plateaued. At 1.6 g/h of CaGlu, plasma [Ca2+] fell by 6% after 20 to 30 minutes and then plateaued. The difference at 40 to 50 minutes was significant (P = .015). Hypocalcemic reactions were noted in three patients during 5 of 17 TPE at 1.0 g/h (all after 40 to 60 minutes) but 0 of 17 TPE at 1.6 g/h (P = .044). CaGlu at 1.6 g/h stabilized plasma [Ca2+] and appears to prevent hypocalcemic reactions during TPE.
- 11 August 2018
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 33 (5) , 600-603
Prophylactic infusion of calcium gluconate to prevent a symptomatic fall in plasma ionized calcium during therapeutic plasma exchange: A comparison of two methods
We compared two methods of calcium gluconate infusion to maintain plasma ionized calcium ([Ca2+]) during therapeutic plasma exchange (TPE) performed using the Spectra Optia Apheresis System. Method A, our legacy method, consisted of adding 5 mL of 10% calcium gluconate to each 500 mL bottle of 5% albumin replacement fluid. Method B used an accessory IV infusion of calcium gluconate (2 g in 50 mL of 0.9% NaCl starting at 25 mL/h). Plasma [Ca2+] was measured at 20‐minute intervals, and symptoms of hypocalcemia were recorded during TPE. Baseline [Ca2+] was the same (P = 0.616), as was total acid citrate dextrose Formula A used (P = 0.865), with either method. TPE with method A used 2.62 ± 0.52 g of calcium gluconate vs 1.13 ± 0.27 g with method B (P < 0.001). [Ca2+] remained stable with method A (P = 0.251), but fell on average by 5% with method B (P < 0.05). Hypocalcemic symptoms were reported in 0 of 23 TPE with method A and 2 of 24 TPE with method B. We conclude that both methods A and B prevent a symptomatic fall in plasma [Ca2+] during TPE. Method B requires significantly less calcium gluconate than does method A.
- 11 August 2018
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 33 (5) , 600-603
Prophylactic infusion of calcium gluconate to prevent a symptomatic fall in plasma ionized calcium during therapeutic plasma exchange: A comparison of two methods
We compared two methods of calcium gluconate infusion to maintain plasma ionized calcium ([Ca2+]) during therapeutic plasma exchange (TPE) performed using the Spectra Optia Apheresis System. Method A, our legacy method, consisted of adding 5 mL of 10% calcium gluconate to each 500 mL bottle of 5% albumin replacement fluid. Method B used an accessory IV infusion of calcium gluconate (2 g in 50 mL of 0.9% NaCl starting at 25 mL/h). Plasma [Ca2+] was measured at 20‐minute intervals, and symptoms of hypocalcemia were recorded during TPE. Baseline [Ca2+] was the same (P = 0.616), as was total acid citrate dextrose Formula A used (P = 0.865), with either method. TPE with method A used 2.62 ± 0.52 g of calcium gluconate vs 1.13 ± 0.27 g with method B (P < 0.001). [Ca2+] remained stable with method A (P = 0.251), but fell on average by 5% with method B (P < 0.05). Hypocalcemic symptoms were reported in 0 of 23 TPE with method A and 2 of 24 TPE with method B. We conclude that both methods A and B prevent a symptomatic fall in plasma [Ca2+] during TPE. Method B requires significantly less calcium gluconate than does method A.